| 引用本文:王媛媛，谢国祥.丹参酮ⅡA磺酸钠联合胺碘酮治疗急性心肌梗死并心房颤动的Meta分析[J].世界中医药,2021,(05):. |
|
| 丹参酮ⅡA磺酸钠联合胺碘酮治疗急性心肌梗死并心房颤动的Meta分析 |
| Meta Analysis of Efficacy of Tanshinone ⅡA Sulfonate Combined with Amiodarone in the Treatment of Acute Myocardial Infarction Complicated with Atrial Fibrillation |
| 投稿时间：2019-11-06 |
| DOI：10.3969/j.issn.1673-7202.2021.05.018 |
| 中文关键词: 丹参酮ⅡA磺酸钠 胺碘酮 联合治疗 急性心肌梗死 冠心病 心房颤动 心律失常 Meta分析 |
| English Keywords:Tanshinone ⅡA sulfonate Amiodarone Combination therapy Acute myocardial infarction Coronary heart disease Atrial fibrillation Arrhythmology Meta analysis |
| 基金项目:国家自然科学基金项目（81760058） |
|
| 摘要点击次数: 613 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的：系统评价丹参酮ⅡA磺酸钠联合胺碘酮治疗急性心肌梗死合并心房颤动的疗效及安全性。方法：检索PubMed、Cochrane library、EMBase、国家知识基础设施数据库（简称中国知网，China National Knowledge Infrastructure，CNKI）、中文科技期刊数据库（简称维普资讯，Chinese Citation Database，CCD）、中国学术期刊数据库（简称万方数据库，China Science Periodical Database，CSPD），查找所有关于丹参酮ⅡA磺酸钠联合胺碘酮治疗急性心肌梗死合并心房颤动的随机对照研究文献，采用RevMan 5.3软件进行Meta分析。结果：10篇文献纳入研究，共计1 088例患者，其中观察组549例，对照组539例。Meta分析结果显示，观察组房颤转复有效率（OR=3.10，95%CI为2.16~4.44，P<0.05）、房颤复发率（OR=0.32，95%CI为0.22~0.48，P<0.05）、心力衰竭发生率（OR=0.23，95%CI为0.15~0.35，P<0.05）、死亡率（OR=0.23，95%CI为0.15~0.35，P<0.05）、治疗后血清CRP水平（MD=-1.15，95%CI为-1.69~-0.61，P<0.05）及不良反应率（OR=0.24，95%CI为0.12~0.49，P<0.05）均优于对照组。结论：丹参酮ⅡA磺酸钠联合胺碘酮治疗急性心肌梗死合并心房颤动安全可靠，但尚需更多高质量的随机对照研究为临床提供证据。 |
| English Summary: |
| To systematically evaluate the efficacy and safety of Tanshinone ⅡA sulfonate combined with amiodarone in the treatment of acute myocardial infarction complicated with atrial fibrillation.Methods:PubMed,Cochrane library,Embase,CNKI,Wanfang,VIP were retrieved.All randomized controlled trial study literature which about the K tanshinone ⅡA sulfonate combined with amiodarone in the treatment of acute myocardial infarction complicated with atrial fibrillation were collected.Meta analysis was performed to evaluate the data by using RevMan5.3 software.Results:A total of 10 papers were included in the study,with a total of 1088 patients.The experimental group was 549 cases and the control group was 539 cases.Meta analysis results showed:The success rate of AF conversion of the experimental group was better than that of the control group［OR=3.10,95%CI(2.16~4.44),P<0.05］.The recurrence rate of atrial fibrillation［OR=0.32,95%CI(0.22~0.48),P<0.05］.The incidence of heart failure of the experimental group ［OR=0.23,95%CI(0.15~0.35),P<0.05］.The mortality ［OR=0.23,95%CI(0.15~0.35),P<0.05］.Heart failure incidence ［OR=0.23,95%CI(0.15~0.35),P<0.05］,mortality ［OR=0.23,95%CI(0.15~0.35),P<0.05］,the CRP level after treatment ［MD=-1.15，95%CI(-1.69~-0.61),P<0.05］.The adverse reactions rate ［OR=0.24，95%CI(0.12~0.49),P<0.05］.Conclusion:Tanshinone ⅡA sulfonate combined with amiodarone is safe and reliable in the treatment of acute myocardial infarction complicated with atrial fibrillation.However,more high-quality randomized controlled studies are needed to provide clinical evidence. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
|
|
|
